Respiratory Drug Market
Global Respiratory Drug market By Route of Administration (Oral, Injectable and Inhalable), By Application (Asthma and Chronic Obstructive Pulmonary Disease (COPD)), and By End-User (Homecare and Hospitals and Clinics) Forecast Period (2021-2027)
The global respiratory drug market is growing at a considerable CAGR of 6.5% during the forecast period. Increasing pervasiveness of chronic respiratory diseases is one of the prime factors affecting and driving the market. Increasing development of new products and increasing number of cases in children related to respiratory diseases is also estimated to be the prime factors that are contributing significantly towards the growth of the market. However, strict government rules and regulations are major factors constraints that are hindering the growth of the global respiratory drug market across the globe.
However, increasing demand for home care products is one of the key factors that are creating opportunity for the market. New product launches in the market are likely to drive the growth of the global respiratory drug market. For instance, in September 2020, Verona Pharma plc one of the companies that is clinical stage bio-pharmaceutical which emphasis on diseases related to respiratory had set forth the symptom data related to phase 2b Chronic Obstructive Pulmonary Disease (COPD). This was done in international journal of Chronic Obstructive Pulmonary Disease which highlighted the fact through this data that ensifentrine had produced improvements in functionality of lung through its all doses along with progressive betterment in symptoms related to Chronic Obstructive Pulmonary Disease.
Impact of COVID-19 on the Global Respiratory drug market
The global respiratory drug market is hardly hit by the COVID-19 pandemic since December 2019. The COVID-19 pandemic in the major economies had disrupted the manufacturing and transportation activities. However, with the lockdown restriction lifted it is likely to increase the output for respiratory drug devices for patients.
Segmental Outlook
The market is segmented based on route of administration, application and end-user. Based on route of administration, the market is segmented into oral, injectable and inhalable. By application, the market is segmented into asthma and chronic obstructive pulmonary disease (COPD). By end-user, market is segmented into homecare and hospitals and clinics.
Global Respiratory drug market Share by End- User 2020 (%)
Based on the end-user, hospitals and clinics holds a significant share in the market. Respiratory drug along with device are mostly used and needed in the hospitals for providing proper treatment to the patient. Initially, most of the products in healthcare sector are designed for the hospitals only. Generally, the requirement of hospitals with regards to equipment related to respiratory are of two types. Firstly that can be used in emergency situations such as in ambulance and secondly it can be fixed equipment that is used in hospitals. The manufacturing company provides the equipment that are having longer life cycle with better effectiveness.
Regional Outlooks
The global respiratory drug market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America held a considerable share in 2020 in the global respiratory drug market. Some factors that are boosting the market growth in North America are growing geriatric population, leading manufactures and players present in the region. Additionally, increasing pervasiveness of chronic respiratory diseases along with technology advancement is some other factors that are promoting the growth of the market.
Global Respiratory Drug market, by Region 2021-2027
Asia-Pacific will have Considerable Growth in the Global Respiratory Drug market
Asia-Pacific region is expected to witness significant growth opportunities for the market. Large scale population affected with asthma and chronic obstructive pulmonary disease along with increasing awareness regarding the treatment of the asthma and chronic obstructive pulmonary disease in the region are likely to drive the growth of the regional market. Further due to rising health care expenditure along with increasing R&D by market player in India, China and South Korea are also some of the factors that are affecting and impacting the growth in this market.
Market Player Outlook
Key players of the global respiratory drug market are AstraZeneca, Boehringer Ingelheim International GmbH., GlaxoSmithKline plc. Koninklijke Philips N.V., and OMRON corp., among others. To survive in the market, these players adopt different marketing strategies such as product launches, collaboration. For instance, in July 2020, Novartis AG has put forward the results from second phase IRIDIUM study. This study result indicates that one daily treatment dose which is high and medium of enerzair; breezhaler had highlighted the improvement in functionality of lung along with asthma.
In June2019, Theravance Biopharma along with Mylan N.V. had entered into agreement in order to expand the development and commercialization regards to nebulized bronchodilator in China. Revefenacin is offered with the name Yupelri that is one in a day to be used nebulized bronchodilator for which it had also got the approval in the US for Chronic Obstructive Pulmonary Disease (COPD). Moreover, now it will give effective treatment to around 100 million patients suffering from Chronic Obstructive Pulmonary Disease (COPD) in china.
The Report Covers
• Market value data analysis of 2020 and forecast to 2027.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global respiratory drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Respiratory Drug Industry
• Recovery Scenario of Global Respiratory Drug Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Respiratory Drug Market by Route of Administration
5.1.1. Oral
5.1.2. Injectable
5.1.3. Inhalable
5.2. Global Respiratory Drug Market by Application
5.2.1. Asthma
5.2.2. Chronic Obstructive Pulmonary Disease (COPD)
5.3. Global Respiratory Drug Market by End-User
5.3.1. Homecare
5.3.2. Hospitals and Clinics
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Air Liquide
7.2. AstraZeneca
7.3. Bausch Health Companies Inc.
7.4. Baxter
7.5. Beximco Pharmaceuticals Ltd.
7.6. Boehringer Ingelheim International GmbH.
7.7. Compumedics Ltd.
7.8. Medtronic
7.9. Dragerwerk AG & Co. KGaA,
7.10. F. Hoffmann-La Roche Ltd
7.11. Fisher & Paykel Healthcare Ltd.
7.12. GENERAL ELECTRIC CO.
7.13. GlaxoSmithKline plc.
7.14. Grifols, S.A
7.15. Hamilton Medical
7.16. KONINKLIJKE PHILIPS N.V.
7.17. Merck & Co.
7.18. Methapharm Inc.
7.19. Mylan N.V.
7.20. Nephron Pharmaceuticals Corp.
7.21. NovaBiotics Ltd
7.22. Novartis AG
7.23. OMRON Corp.
7.24. OPKO Health, Inc.
7.25. Pfizer Inc.
7.26. Savara Inc.
7.27. Sunovion Pharmaceuticals Inc.
7.28. Teva Pharmaceutical Industries Ltd.
7.29. Theravance Biopharma, Inc.
7.30. United Therapeutics Corp.
7.31. Viatris Inc.
7.32. Verona Pharma plc
1. GLOBAL RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
2. GLOBAL RESPIRATORY DRUG MARKET BY ROUTE OF ADMINISTRATION, 2020-2027($ MILLION)
3. GLOBAL ORAL RESPIRATORY DRUG MARKET BY REGION, 2020-2027($ MILLION)
4. GLOBAL INJECTABLE RESPIRATORY DRUG MARKET BY REGION, 2020-2027($ MILLION)
5. GLOBAL INHALABLE RESPIRATORY DRUG MARKET BY REGION, 2020-2027 ($ MILLION)
6. GLOBAL RESPIRATORY DRUG MARKET BY APPLICATION, 2020-2027($ MILLION)
7. GLOBAL ASTHMA RESPIRATORY DRUG MARKET BY REGION, 2020-2027($ MILLION)
8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) RESPIRATORY DRUG MARKET BY REGION, 2020-2027($ MILLION)
9. GLOBAL RESPIRATORY DRUG MARKET BY END-USER, 2020-2027($ MILLION)
10. GLOBAL HOMECARE RESPIRATORY DRUG MARKET BY REGION, 2020-2027($ MILLION)
11. GLOBAL HOSPITALS AND CLINICS RESPIRATORY DRUG MARKET BY REGION, 2020-2027($ MILLION)
12. GLOBAL RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
13. NORTH AMERICAN RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
14. NORTH AMERICAN RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2020-2027($ MILLION)
15. NORTH AMERICAN RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
16. NORTH AMERICAN RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
17. EUROPEAN RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
18. EUROPEAN RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2020-2027($ MILLION)
19. EUROPEAN RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
20. EUROPEAN RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
21. ASIA-PACIFIC RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
22. ASIA-PACIFIC RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BYROUTE OF ADMINISTRATION, 2020-2027($ MILLION)
23. ASIA-PACIFIC RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
24. ASIA-PACIFIC RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
25. REST OF THE WORLD RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BYROUTE OF ADMINISTRATION, 2020-2027($ MILLION)
26. REST OF THE WORLD RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
27. REST OF THE WORLD RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL RESPIRATORY DRUG MARKET RESEARCH, 2020-2027 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL RESPIRATORY DRUG MARKET RESEARCH SHARE BY SEGMENT, 2020-2027 ($ MILLION)
3. RECOVERY OF GLOBAL RESPIRATORY DRUG MARKET RESEARCH, 2021-2027 (%)
4. GLOBAL RESPIRATORY DRUG MARKET RESEARCH SHARE BY ROUTE OF ADMINISTRATION, 2020 VS 2027 (%)
5. GLOBAL RESPIRATORY DRUG MARKET RESEARCH SHARE BY APPLICATION, 2020 VS 2027 (%)
6. GLOBAL RESPIRATORY DRUG MARKET RESEARCH SHARE BY END-USER, 2020 VS 2027 (%)
7. GLOBAL RESPIRATORY DRUG MARKET RESEARCH SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
8. GLOBAL ORAL RESPIRATORY DRUG MARKET BY REGION, 2020 VS 2027 (%)
9. GLOBAL INJECTABLE RESPIRATORY DRUG MARKET BY REGION, 2020 VS 2027 (%)
10. GLOBAL INHALABLE RESPIRATORY DRUG MARKET BY REGION, 2020 VS 2027 (%)
11. GLOBAL ASTHMA RESPIRATORY DRUG MARKET BY REGION, 2020 VS 2027 (%)
12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)RESPIRATORY DRUG MARKET BY REGION, 2020 VS 2027 (%)
13. GLOBAL HOMECARE RESPIRATORY DRUG MARKET BY REGION, 2020 VS 2027 (%)
14. GLOBAL HOSPITALS AND CLINICS RESPIRATORY DRUG MARKET BY REGION, 2020 VS 2027 (%)
15. US RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
16. CANADA RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
17. UK RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
18. FRANCE RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
19. GERMANY RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
20. ITALY RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
21. SPAIN RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
22. REST OF EUROPE RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
23. INDIA RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
24. CHINA RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
25. JAPAN RESPIRATORY DRUG MARKET RESEARCH T SIZE, 2020-2027 ($ MILLION)
26. SOUTH KOREA RESPIRATORY DRUG MARKET SIZE, 2020-2027 ($ MILLION)
27. REST OF ASIA-PACIFIC RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
28. REST OF THE WORLD RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
